摘要
Background Peripheral artery disease accounts for more than 400 000 hospitalizations in the USA and results in symptoms ranging from claudication to gangrene. Recent advances in endovascular techniques have led to a more aggressive approach for treating peripheral artery disease. The aim of this retrospective study was to evaluate the outcomes of endovascular interventions on TransAtlantic InterSociety Consensus （TASC） Ⅱ C and D femoropopliteal occlusive disease. Methods Data for all patients undergoing endovascular interventions for femoropopliteal occlusive disease from December 2007 through December 2010 were reviewed. Demographic data, risk factor data, preprocedural and postprocedural ankle-brachial indices, technical success rates, and complication rates were obtained. Primary, assisted primary, and secondary patency were determined by Kaplan-Meier survival analysis. Univariate and multivariate analyses were performed to identify factors adversely affecting primary patency. Results The study group included 52 TASC Ⅱ C and 106 TASC Ⅱ D limbs in 126 patients （mean age, （68.0±18.0） years） The technical success rate was 91.1%. Complications occurred in 19 limbs （12.0%）, including 8 （5.1%） major complications. The mean follow-up period was （17.6±5.1） months （range, 12.0-48.0 months）. Primary patency rates at 1, 2, 3, and 4 years were 95%, 78%, 74%, and 74% in TASC Ⅱ C lesions and 89%, 62%, 52%, and 52% in TASC Ⅱ D lesions, respectively. Secondary patency rates at 1, 2, 3, and 4 years were 97%, 94%, 94%, and 94% in TASC Ⅱ C lesions and 97%, 95%, 83%, and 83% in TASC Ⅱ D lesions, respectively. It is significantly different between primary patency rates （P 〈0.05） but not secondary patency rates of TASC Ⅱ C and D groups （P 〉0.05）. Predictors of restenosis/occlusion included hyperlipidemia, lesion length, and popliteal artery involvement. Conclusions Endovascular treatment of TASC Ⅱ C and D femoropopliteal artery occlusion has a high technical success rate with favorable mid-term secondary patency rate. Hyperlipidemia, lesion length, and popliteal artery involvement were independent risk factors for in-stent restenosis.
Background Peripheral artery disease accounts for more than 400 000 hospitalizations in the USA and results in symptoms ranging from claudication to gangrene. Recent advances in endovascular techniques have led to a more aggressive approach for treating peripheral artery disease. The aim of this retrospective study was to evaluate the outcomes of endovascular interventions on TransAtlantic InterSociety Consensus （TASC） Ⅱ C and D femoropopliteal occlusive disease. Methods Data for all patients undergoing endovascular interventions for femoropopliteal occlusive disease from December 2007 through December 2010 were reviewed. Demographic data, risk factor data, preprocedural and postprocedural ankle-brachial indices, technical success rates, and complication rates were obtained. Primary, assisted primary, and secondary patency were determined by Kaplan-Meier survival analysis. Univariate and multivariate analyses were performed to identify factors adversely affecting primary patency. Results The study group included 52 TASC Ⅱ C and 106 TASC Ⅱ D limbs in 126 patients （mean age, （68.0±18.0） years） The technical success rate was 91.1%. Complications occurred in 19 limbs （12.0%）, including 8 （5.1%） major complications. The mean follow-up period was （17.6±5.1） months （range, 12.0-48.0 months）. Primary patency rates at 1, 2, 3, and 4 years were 95%, 78%, 74%, and 74% in TASC Ⅱ C lesions and 89%, 62%, 52%, and 52% in TASC Ⅱ D lesions, respectively. Secondary patency rates at 1, 2, 3, and 4 years were 97%, 94%, 94%, and 94% in TASC Ⅱ C lesions and 97%, 95%, 83%, and 83% in TASC Ⅱ D lesions, respectively. It is significantly different between primary patency rates （P 〈0.05） but not secondary patency rates of TASC Ⅱ C and D groups （P 〉0.05）. Predictors of restenosis/occlusion included hyperlipidemia, lesion length, and popliteal artery involvement. Conclusions Endovascular treatment of TASC Ⅱ C and D femoropopliteal artery occlusion has a high technical success rate with favorable mid-term secondary patency rate. Hyperlipidemia, lesion length, and popliteal artery involvement were independent risk factors for in-stent restenosis.
